MYC and lymphoma: Furthermore, when modified with a chimeric antigen receptor (CAR), selective tropism is given leading to specific particle accumulation in tumor cells, followed by CRISPR/Cas9 system release and subsequent targeting of the MYC oncogene in lymphoma (177).